Home LiteratureArticle Details
PMID: 9765439 Published · ppublish English Case Reports Journal Article Research Support, Non-U.S. Gov't

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

Journal of virology ·Vol. 72 ·No. 11 ·1998-11-00 ·Pages 8943-51

Lewis J, Balfe P, Arnold C, Kaye S, Tedder RS, McKeating JA

Abstract

We monitored the primary humoral response to human immunodeficiency virus type 1 infection and showed that, in addition to antibodies to p24 and gp41, antigens which form the basis of most diagnostic assays, the response included a significant antibody response directed to the gp120 region of the infecting viral quasispecies. When tested in a recombinant virus neutralization assay, these antibodies were capable of inhibiting viral growth. We found the primary viral quasispecies to solely utilize the CCR-5 chemokine receptor; however, recombinant viruses differed in their cytopathology and in their sensitivity to beta-chemokine inhibition of viral growth. Sequence analysis of the gp120 open reading frames showed that amino acid changes in the C1 (D-->G at position 62) and C4 (V-->A at position 430) regions accounted for the phenotypic differences. These data demonstrate that early in infection, polymorphism exists in envelope glycoprotein coreceptor interactions and imply that therapeutic strategies targeted at this step in the viral life cycle may lead to rapid resistance.

MeSH Terms
Amino Acid Sequence Antigenic Variation Chimera/genetics Cytopathogenic Effect, Viral/genetics,immunology HIV Antibodies/blood HIV Antigens/blood,genetics HIV Core Protein p24/blood HIV Envelope Protein gp120/blood,genetics HIV Seropositivity/immunology,virology HIV-1/genetics,immunology,isolation & purification Humans Molecular Sequence Data Neutralization Tests Open Reading Frames Phenotype Receptors, CCR5/physiology Time Factors Viremia/immunology,virology
Chemicals
HIV Antibodies HIV Antigens HIV Core Protein p24 HIV Envelope Protein gp120 Receptors, CCR5
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Lewis J
School of Animal and Microbial Sciences, University of Reading, Reading RG6 2AJ, United Kingdom.
Balfe P
Arnold C
Kaye S
Tedder R S
McKeating J A
References (71)
71 references, click to expand
  1. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism.
    J Virol. 1997 Oct;71(10):8001-7 PMID: 9311895
  2. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups.
    J Virol. 1997 Oct;71(10):8008-13 PMID: 9311896
  3. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
    J Infect Dis. 1997 Oct;176(4):924-32 PMID: 9333150
  4. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
    Nat Med. 1997 Nov;3(11):1259-65 PMID: 9359702
  5. CCR5 is characteristic of Th1 lymphocytes.
    Nature. 1998 Jan 22;391(6665):344-5 PMID: 9450746
  6. Analysis of human immunodeficiency virus type 1 (HIV-1) variants and levels of infection in dendritic and T cells from symptomatic HIV-1-infected patients.
    J Gen Virol. 1998 Feb;79 ( Pt 2):247-57 PMID: 9472609
  7. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy.
    Nat Med. 1998 Mar;4(3):341-5 PMID: 9500610
  8. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
    J Virol. 1993 Sep;67(9):5216-25 PMID: 7688820
  9. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope.
    J Exp Med. 1994 Feb 1;179(2):463-72 PMID: 8294860
  10. Sequence variation within the human immunodeficiency virus V3 loop at seroconversion.
    J Med Virol. 1993 Dec;41(4):270-4 PMID: 8106860
  11. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  12. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):5142-55 PMID: 8035514
  13. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  14. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes.
    Cell. 1994 Aug 12;78(3):373-87 PMID: 7914835
  15. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
    J Virol. 1989 May;63(5):2118-25 PMID: 2564898
  16. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    AIDS. 1990 Feb;4(2):107-12 PMID: 2328092
  17. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
    AIDS. 1990 Apr;4(4):297-305 PMID: 2190604
  18. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.
    J Virol. 1990 Dec;64(12):5701-7 PMID: 2243375
  19. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.
    J Virol. 1991 Jan;65(1):356-63 PMID: 1985204
  20. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.
    J Virol. 1991 Apr;65(4):2119-23 PMID: 2002555
  21. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
    N Engl J Med. 1991 Apr 4;324(14):954-60 PMID: 1900576
  22. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.
    N Engl J Med. 1991 Apr 4;324(14):961-4 PMID: 1823118
  23. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
    J Virol. 1992 Mar;66(3):1354-60 PMID: 1738194
  24. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.
    J Infect Dis. 1992 Mar;165(3):427-32 PMID: 1347054
  25. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.
    J Virol. 1992 Jun;66(6):3531-7 PMID: 1583722
  26. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain.
    J Virol. 1992 Oct;66(10):6175-80 PMID: 1527855
  27. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.
    J Med Virol. 1992 Aug;37(4):241-6 PMID: 1383414
  28. Transmission and pathogenesis of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):321-3 PMID: 8068409
  29. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
    Virology. 1994 Oct;204(1):223-33 PMID: 7916514
  30. The biological phenotype of HIV-1 is usually retained during and after sexual transmission.
    Virology. 1994 Oct;204(1):297-303 PMID: 8091660
  31. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1994 Nov;68(11):6836-47 PMID: 7933065
  32. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Virology. 1994 Nov 1;204(2):609-15 PMID: 7941328
  33. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
    J Infect Dis. 1994 Nov;170(5):1141-7 PMID: 7963706
  34. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
    J Virol. 1995 Jan;69(1):222-30 PMID: 7527084
  35. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection.
    Immunol Rev. 1994 Aug;140:105-30 PMID: 7821924
  36. Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.
    AIDS Res Hum Retroviruses. 1995 Mar;11(3):335-42 PMID: 7786580
  37. Sequence distances between env genes of HIV-1 from individuals infected from the same source: implications for the investigation of possible transmission events.
    Virology. 1995 Aug 1;211(1):198-203 PMID: 7645211
  38. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.
    Nat Med. 1996 Apr;2(4):412-7 PMID: 8597950
  39. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Apr;72(4):2855-64 PMID: 9525605
  40. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.
    J Virol. 1998 May;72(5):4032-7 PMID: 9557691
  41. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate.
    J Virol. 1998 May;72(5):4478-84 PMID: 9557745
  42. Development of HIV-1 group-specific neutralizing antibodies after seroconversion.
    AIDS. 1992 Aug;6(8):799-802 PMID: 1418776
  43. Assessment of HIV-1 antigenic diversification using serum as sample source.
    AIDS Res Hum Retroviruses. 1992 Aug;8(8):1473 PMID: 1466985
  44. Predictors of rapid progression to AIDS in HIV-1 seroconverters.
    AIDS. 1993 Jan;7(1):51-7 PMID: 8095146
  45. The role of the V3 loop of gp120 in HIV infection.
    AIDS. 1991;5 Suppl 2:S21-33 PMID: 1845049
  46. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.
    J Virol. 1993 Jun;67(6):3345-56 PMID: 8497055
  47. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    J Infect Dis. 1993 Jul;168(1):207-10 PMID: 8515110
  48. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission.
    J Virol. 1996 May;70(5):3098-107 PMID: 8627789
  49. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    Science. 1996 May 10;272(5263):872-7 PMID: 8629022
  50. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV.
    Science. 1996 Mar 1;271(5253):1291-3 PMID: 8638113
  51. Functional characterization of the V1V2 region of human immunodeficiency virus type 1.
    Virology. 1996 Jun 15;220(2):436-49 PMID: 8661394
  52. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    Virology. 1996 Jun 15;220(2):450-60 PMID: 8661395
  53. Identification of a major co-receptor for primary isolates of HIV-1.
    Nature. 1996 Jun 20;381(6584):661-6 PMID: 8649511
  54. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
    Nature. 1996 Jun 20;381(6584):667-73 PMID: 8649512
  55. Evidence for limited within-person evolution of the V3 domain of the HIV-1 envelope in the amsterdam population.
    AIDS. 1996 Jan;10(1):31-7 PMID: 8924249
  56. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
    Cell. 1996 Jun 28;85(7):1135-48 PMID: 8674119
  57. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
    Cell. 1996 Jun 28;85(7):1149-58 PMID: 8674120
  58. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
    Science. 1996 Jun 28;272(5270):1955-8 PMID: 8658171
  59. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
    Cell. 1996 Aug 9;86(3):367-77 PMID: 8756719
  60. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
    Nature. 1996 Aug 22;382(6593):722-5 PMID: 8751444
  61. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
    Science. 1996 Sep 27;273(5283):1856-62 PMID: 8791590
  62. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection.
    J Virol. 1996 Oct;70(10):7285-9 PMID: 8794384
  63. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1.
    J Infect Dis. 1997 Jan;175(1):231-2 PMID: 8985228
  64. Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.
    J Virol. 1997 Jan;71(1):759-65 PMID: 8985413
  65. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Nat Med. 1997 Feb;3(2):205-11 PMID: 9018240
  66. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.
    Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30 PMID: 9050881
  67. HIV-1 infection in an individual homozygous for the CCR5 deletion allele.
    Nat Med. 1997 Mar;3(3):252-3 PMID: 9055842
  68. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.
    J Virol. 1997 Apr;71(4):2799-809 PMID: 9060635
  69. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    J Virol. 1997 May;71(5):3734-41 PMID: 9094648
  70. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.
    J Virol. 1997 Jun;71(6):4479-84 PMID: 9151839
  71. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.
    J Exp Med. 1997 May 5;185(9):1681-91 PMID: 9151905
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.72.11.8943-8951.1998
Published
1998-11-00
Pages
8943-51
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC110311
Subset
IM
Grants
Wellcome Trust · United Kingdom
Databases
GENBANK
AJ007943, AJ007944, AJ007945, AJ007946, AJ007947, AJ007948
External Links
PubMed source DOI: 10.1128/JVI.72.11.8943-8951.1998 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2